Core Viewpoint - Several companies are projected to experience significant growth in net profit for 2025, with increases ranging from over 16% to more than 1400% compared to the previous year [1] Group 1: Company Projections - Nanfang Precision is expected to see a net profit increase of 1130% to 1417% in 2025 [1] - Jin'an Guoji anticipates a net profit growth of 655.53% to 871.4% for 2025 [1] - Limin Co. forecasts a net profit rise of 471.55% to 514.57% in 2025 [1] - Hekang New Energy projects a net profit increase of 386% to 628% for 2025 [1] - Baiao Intelligent expects a net profit growth of 228.34% to 337.79% in 2025 [1] - Dajin Heavy Industry anticipates a net profit increase of 121.58% to 153.23% for 2025 [1] - Yinhui Technology projects a net profit rise of 114% to 133% in 2025 [1] - Demingli expects a net profit increase of 85% to 128% for 2025 [1] - Juhua Co. forecasts a net profit growth of 80% to 101% in 2025 [1] - Ganli Pharmaceutical anticipates a net profit increase of 78.96% to 95.23% for 2025 [1] - Tongfei Co. projects a net profit rise of 56.43% to 74.68% in 2025 [1] - Jiajia Yue expects a net profit increase of 50.06% to 72.79% for 2025 [1] - Tianfu Communication anticipates a net profit growth of 40% to 60% in 2025 [1] - Shunke Zhilian projects a net profit increase of 34.94% to 59.47% for 2025 [1] - Feilihua expects a net profit rise of 31.12% to 50.22% in 2025 [1] - Hailide anticipates a net profit increase of 21.78% to 31.53% for 2025 [1] - Ligao Food projects a net profit growth of 16.06% to 23.52% in 2025 [1]

证券日报网讯 1月21日，甘李药业发布2025年年度业绩预增公告称，公司预计2025年年度现归属于母公 司所有者的净利润为11.00亿元到12.00亿元，与上年同期（法定披露数据）相比，将增加4.85亿元到5.85 亿元，同比增加78.96%到95.23%。 （文章来源：证券日报） ...

Core Viewpoint - Gannee Pharmaceutical (603087.SH) expects a significant increase in net profit for the year 2025, projecting a net profit attributable to shareholders of the parent company between 1.1 billion to 1.2 billion yuan, representing an increase of 4.85 billion to 5.85 billion yuan compared to the previous year, which translates to a year-on-year growth of 78.96% to 95.23% [1] Group 1: Domestic Market Performance - The company has leveraged its market coverage advantage gained from centralized procurement to deepen and expand its market presence, resulting in substantial growth in both sales volume and revenue of insulin preparation products [1] Group 2: International Market Strategy - The company is actively advancing its internationalization strategy, achieving significant results in emerging markets along the "Belt and Road" initiative, successfully gaining the trust and cooperation of more international clients, leading to sales growth in several key markets [1] Group 3: Equity Transfer and Profit Increase - In 2025, the company reached an agreement with Guangdong Hengqin Ganling Enterprise Management Co., Ltd. to transfer a total of 70% equity of its wholly-owned subsidiary, Gannee Medical Technology Jiangsu Co., Ltd., in two phases. The first phase has been completed, with 55% of the equity successfully transferred, resulting in increased investment income and contributing to the rise in net profit [1]

Core Viewpoint - Ganli Pharmaceutical (603087.SH) expects a significant increase in net profit for the year 2025, projecting a net profit attributable to shareholders of the parent company between 1.1 billion to 1.2 billion yuan, representing a year-on-year increase of 78.96% to 95.23% compared to the previous year [1] Group 1: Financial Performance - The company anticipates a net profit increase of 485 million to 585 million yuan compared to the previous year [1] - The projected net profit growth is primarily driven by revenue growth in domestic and international markets, as well as gains from equity transfers [1] Group 2: Domestic Market Strategy - In the domestic market, the company has leveraged its market coverage advantage gained from centralized procurement, leading to significant growth in both sales volume and revenue of insulin preparations [1] Group 3: International Market Strategy - The company is actively advancing its internationalization strategy, achieving notable success in emerging markets along the "Belt and Road" initiative, resulting in increased sales and trust from international clients [1] Group 4: Equity Transfer - In 2025, the company reached an agreement to transfer 70% of the equity of its wholly-owned subsidiary, Gan Medical Technology Jiangsu Co., Ltd., to Guangdong Hengqin Ganling Enterprise Management Co., Ltd. in two phases [1] - The first phase of the transaction has been completed, with 55% of the equity successfully transferred, contributing to increased investment income and net profit [1]

北京商报讯（记者 丁宁）1月21日晚间，甘李药业（603087）发布2025年年度业绩预告显示，公司预计 2025年年度实现归属净利润为11亿元到12亿元，与上年同期（法定披露数据）相比，将增加4.85亿元到 5.85亿元，同比增加78.96%到95.23%。 甘李药业表示，2025年度，公司预计归属净利润较去年同期实现大幅增长，主要受益于国内外收入增 长、股权转让收益。 ...

北京商报讯（记者 王寅浩 宋雨盈）1月21日，甘李药业发布2025年业绩预告，公司预计2025年实现归属 于母公司所有者的净利润为11亿—12亿元，同比增加78.96%—95.23%。预计实现归属于母公司所有者 的扣除非经常性损益的净利润为7亿—8亿元，同比增加62.63%到85.86%。 ...

证券代码：603087 证券简称：甘李药业 公告编号：2026-007 甘李药业股份有限公司 北京旭特宏达科技有限公司（以下称"旭特宏达"）持有甘李药业股份 有限公司（以下简称"公司"）无限售条件流通股 32,073,734 股，占公司总股本 的5.37%。公司于2026年1月21日收到通知，旭特宏达已于近日办理完毕700,000 股公司股份的解押登记手续。本次股份解除质押后，旭特宏达累计质押公司股份 数量为 22,710,000 股，占其持股数量的 70.81%，占公司总股本的 3.80%。 控股股东、实际控制人甘忠如先生及其控制的北京旭特宏达科技有限公 司（以下简称"旭特宏达"）合计持有公司股份 237,717,491 股，占公司总股本 的 39.80%。本次股份解除质押后，甘忠如先生及旭特宏达累计质押公司股份数 量为 22,710,000 股，占其持股数量的 9.55%，占公司总股本的 3.80%。 关于公司持股 5%以上股东部分股份解押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: | 股东名称 ...

证券代码：603087 证券简称：甘李药业 公告编号：2026-008 甘李药业股份有限公司 关于完成工商登记信息变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 统一社会信用代码：91110000102382249M 类型：股份有限公司（外商投资、上市） 住所：北京市通州区漷县镇南凤西一路 8 号 法定代表人：陈伟 注册资本：人民币 59730.4969 万元 2025 年 9 月 8 日，甘李药业股份有限公司（以下简称"公司"）已完成自 2024 年 9 月 5 日至 2025 年 9 月 4 日累计通过回购专用证券账户以集中竞价交易 方式实施回购股份 3,540,021 股的回购注销。回购用途为"用于减少注册资本"。 回购注销完成后，公司总股本由 601,065,290 股变更为 597,525,269 股，注册资本 由 601,065,290 元变更为 597,525,269 元。具体内容详见公司在上海证券交易所网 站（www.sse.com.cn）披露的《关于股份回购实施结果暨股份变动的公告》（公 告编号： ...

甘李药业股份有限公司 2025 年年度业绩预增公告 证券代码：603087 证券简称：甘李药业 公告编号：2026-006 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1. 本期业绩预告适用于实现盈利，且净利润与上年同期相比上升 50%以上 的情形。 2. 甘李药业股份有限公司（以下简称"公司"）预计 2025 年年度实现归属于 母公司所有者的净利润为 11.00 亿元到 12.00 亿元，与上年同期（法定披露数据） 相比，将增加 4.85 亿元到 5.85 亿元，同比增加 78.96%到 95.23%。 3. 公司预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益的净 利润为 7.00 亿元至 8.00 亿元，与上年同期（法定披露数据）相比，将增加 2.70 亿元到 3.70 亿元，同比增加 62.63%到 85.86%。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1. 经财务部门初步测算，预计 2025 ...

人民财讯1月21日电，甘李药业（603087）1月21日公告，预计2025年度实现归属于母公司所有者的净利 润为11亿元到12亿元，同比增加78.96%到95.23%。2025年度，公司预计归属于母公司所有者的净利润 较去年同期实现大幅增长，主要受益于国内外收入增长、股权转让收益。 ...